Compare RDNW & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDNW | IVVD |
|---|---|---|
| Founded | 2013 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.8M | 212.6M |
| IPO Year | 2014 | 2021 |
| Metric | RDNW | IVVD |
|---|---|---|
| Price | $4.93 | $0.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $8.50 | ★ $10.00 |
| AVG Volume (30 Days) | 61.8K | ★ 5.6M |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 37.84 | ★ 79.02 |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $1,793,369,000.00 | $53,426,000.00 |
| Revenue This Year | $3.88 | $12.40 |
| Revenue Next Year | $5.55 | $44.85 |
| P/E Ratio | $80.17 | ★ N/A |
| Revenue Growth | 91.10 | ★ 110.47 |
| 52 Week Low | $3.20 | $0.53 |
| 52 Week High | $8.55 | $3.07 |
| Indicator | RDNW | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 35.33 | 33.54 |
| Support Level | $4.60 | $0.53 |
| Resistance Level | $7.14 | $1.02 |
| Average True Range (ATR) | 0.37 | 0.06 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 15.49 | 2.27 |
RideNow Group Inc operates solely as a powersports dealership group. Its offerings include new and pre-owned vehicles such as motorcycles, all-terrain vehicles (ATVs), side-by-side vehicles (SXS), and personal watercraft (PWC). It also sells parts, apparel, and accessories, and provides financing, insurance, and aftermarket products, along with repair and maintenance services. The majority of the company's revenue is derived from powersports vehicle sales, and the rest from parts, service and accessories/merchandise, and finance and insurance products.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.